CD274 and neoplasm: First-line Atezolizumab was compared to standard platinum-based chemotherapy in the randomized phase 3 trial IMpower110 in previously untreated patients with PD-L1 expression of at least 1% of the tumor cells (TC) or of the tumor-infiltrating immune cells (IC).